Allergan PLC shares ticked higher in the extended session Wednesday after the drugmaker said the Food and Drug Administration accepted for review a marketing application for a new acne treatment. Allergan shares rose 0.2% to $166 after hours, following a 2.3% decline in the regular session. The company said the FDA accepted a New Drug Application for Seysara to treat moderate-to-severe acne in patients 9 years old and older. Allergan expects a decision on the application in the second half of 2018. Allergan has the U.S. rights to Seysara, while Paratek Pharmaceuticals Inc. retains rights outside the U.S. Paratek shares rose 4.5% to $18.55 after hours.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News